Feasibility, safety, and efficacy of circumferential spine stereotactic body radiotherapy

Autor: Khaled Dibs, Joshua D. Palmer, Rahul N. Prasad, Alexander Olausson, Eric C. Bourekas, Daniel Boulter, Ahmet S. Ayan, Eric Cochran, William S. Marras, Prasath Mageswaran, Evan Thomas, John Grecula, Michael Guiou, Soheil Soghrati, Esmerina Tili, Raju R. Raval, Ehud Mendel, Thomas Scharschmidt, James B. Elder, Russell Lonser, Arnab Chakravarti, Dukagjin M. Blakaj
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Frontiers in Oncology, Vol 12 (2022)
Druh dokumentu: article
ISSN: 2234-943X
DOI: 10.3389/fonc.2022.912799
Popis: BackgroundWith advances in systemic therapy translating to improved survival in metastatic malignancies, spine metastases have become an increasingly common source of morbidity. Achieving durable local control (LC) for patients with circumferential epidural disease can be particularly challenging. Circumferential stereotactic body radiotherapy (SBRT) may offer improved LC for circumferential vertebral and/or epidural metastatic spinal disease, but prospective (and retrospective) data are extremely limited. We sought to evaluate the feasibility, toxicity, and cancer control outcomes with this novel approach to circumferential spinal disease.MethodsWe retrospectively identified all circumferential SBRT courses delivered between 2013 and 2019 at a tertiary care institution for post-operative or intact spine metastases. Radiotherapy was delivered to 14–27.5 Gy in one to five fractions. Feasibility was assessed by determining the proportion of plans for which ≥95% planning target volume (PTV) was coverable by ≥95% prescription dose. The primary endpoint was 1-year LC. Factors associated with increased likelihood of local failure (LF) were explored. Acute and chronic toxicity were assessed. Detailed dosimetric data were collected.ResultsFifty-eight patients receiving 64 circumferential SBRT courses were identified (median age 61, KPS ≥70, 57% men). With a median follow-up of 15 months, the 12-month local control was 85% (eight events). Five and three recurrences were in the epidural space and bone, respectively. On multivariate analysis, increased PTV and uncontrolled systemic disease were significantly associated with an increased likelihood of LF; ≥95% PTV was covered by ≥95% prescription dose in 94% of the cases. The rate of new or progressive vertebral compression fracture was 8%. There were no myelitis events or any grade 3+ acute or late toxicities.ConclusionsFor patients with circumferential disease, circumferential spine SBRT is feasible and may offer excellent LC without significant toxicity. A prospective evaluation of this approach is warranted.
Databáze: Directory of Open Access Journals